<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914302</url>
  </required_header>
  <id_info>
    <org_study_id>FT6000682013</org_study_id>
    <nct_id>NCT01914302</nct_id>
  </id_info>
  <brief_title>The Characterization of Blood Volumes of Commercially Available Lancing Devices</brief_title>
  <official_title>Lancing Device Blood Volume Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Facet Technologies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LifeScan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Facet Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterize expressed blood volume ≥1μL across representative, commercially available&#xD;
      lancing device systems using finger sticks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      • Characterize expressed blood volume ≥1μL across representative, commercially available&#xD;
      lancing device systems using finger sticks.&#xD;
&#xD;
      Secondary Objectives: the following characterizations will be performed in the data analysis&#xD;
      within each device and across each device:&#xD;
&#xD;
        -  Correlation of Subject pain response to blood volume collected;&#xD;
&#xD;
        -  Proportion of Subjects that produce sufficient blood to fill a 1µl test strip;&#xD;
&#xD;
        -  Proportion of Subjects that generate ≥1µl blood volume;&#xD;
&#xD;
        -  Proportion of Subjects who generate multiple- times the blood volume needed to fill a&#xD;
           1µl test strip&#xD;
&#xD;
        -  Proportion of Subjects who generate multiple- times ≥1µl of blood volume&#xD;
&#xD;
        -  Proportion of Subjects that produce on average (≥1µl) of blood volume on 1st attempt&#xD;
&#xD;
        -  Proportion of Subjects that produce on average (≥1µl) of blood volume on their first and&#xD;
           second lancing attempt&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Volumes measured in microliters</measure>
    <time_frame>between 1 and 10 days after first visit</time_frame>
    <description>Study subject lances assigned finger and acquires blood drop; at that time the study facilitator gathers blood in pipette and measures on scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain rating measure on a 0-20 Gracely Scale</measure>
    <time_frame>between 1 and 10 days after first visit</time_frame>
    <description>Subjects were asked to rate pain on Gracely scale after each lancing even on the finger</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Delica Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Freestyle Flash Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Easy Touch Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucoject Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microlet Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiclix Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fastclix Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reli-On Lancing Device</arm_group_label>
    <description>Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delica Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Delica Lancing Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flash Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Freestyle Flash Lancing Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Easy Touch Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Easy Touch Lancing Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glucoject Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Glucoject Lancing Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microlet Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Microlet Lancing Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multiclix Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Multiclix Lancing Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fastclix Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Fastclix Lancing Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reli-On Lancing Device</intervention_name>
    <description>Characterize Blood Volume and Pain under normal use circumstances</description>
    <arm_group_label>Reli-On Lancing Device</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People with diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be diagnosed with type 1 or type 2 diabetes for one (1) or more year(s).&#xD;
&#xD;
          -  Must be currently self-monitoring blood glucose levels for at least 6 months.&#xD;
&#xD;
          -  Must self-test at least 2 times daily.&#xD;
&#xD;
          -  Must be between the ages of 18 and 75 to participate.&#xD;
&#xD;
          -  Subjects must be able to perform all tasks required in this protocol.&#xD;
&#xD;
          -  Subjects must be willing to complete all study procedures.&#xD;
&#xD;
          -  Subjects must be able to speak, read and understand English and understand the&#xD;
             Informed Consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with neuropathy or any other nerve damage in the hand or fingers (this will&#xD;
             be discovered through the monofilament test)&#xD;
&#xD;
          -  Subjects who are taking prescription anti-coagulants or more than one full aspirin per&#xD;
             day during the past week or have clotting problems that may prolong bleeding (persons&#xD;
             taking Plavix or a daily low dose aspirin will not be excluded but this will be&#xD;
             recorded).&#xD;
&#xD;
          -  Subjects taking pain relievers within 24 hours.&#xD;
&#xD;
          -  Subjects with hemophilia or any other bleeding disorder.&#xD;
&#xD;
          -  Subjects with infection with a blood borne pathogen (e.g., HIV, hepatitis).&#xD;
&#xD;
          -  Subjects having a condition such as a cognitive disorder, which in the opinion of the&#xD;
             Investigator would put the person at risk or seriously compromise the integrity of the&#xD;
             study (PI will sign Case Report Form if Subject is excluded).&#xD;
&#xD;
          -  Subjects working for Facet, LifeScan Inc., or a competitive company.&#xD;
&#xD;
          -  Subjects with missing digits.&#xD;
&#xD;
          -  Subjects who are pregnant or nursing.&#xD;
&#xD;
          -  Subjects on chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Ginsberg, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Facet Technologies</name>
      <address>
        <city>Kennesaw</city>
        <state>Georgia</state>
        <zip>30144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

